I would assume (and i understand this to be the case) that the OxyM trial would be cheap and fast since it just needs to measure theapeutic serum concentrations, whereas the OxyC trial needs to show actual efficacy in a situation never trialled before.
- Forums
- ASX - By Stock
- AVE
- Chart, Cash and Scenarios
Chart, Cash and Scenarios, page-28
Featured News
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $1.32K | 440K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 40522233 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 40065430 | 31 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
30 | 40522233 | 0.002 |
32 | 75717741 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 39315430 | 30 |
0.004 | 30596565 | 18 |
0.005 | 10575266 | 9 |
0.006 | 10908952 | 10 |
0.007 | 13396103 | 7 |
Last trade - 14.05pm 15/11/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online